Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer.

Nature communications - 13 Mar 2017

Uchibori Ken, Inase Naohiko, Araki Mitsugu, Kamada Mayumi, Sato Shigeo, Okuno Yasushi, Fujita Naoya, Katayama Ryohei

Abstract excerpt

Osimertinib has been demonstrated to overcome the epidermal growth factor receptor (EGFR)-T790M, the most relevant acquired resistance to first-generation EGFR-tyrosine kinase inhibitors (EGFR-TKIs). However, the C797S mutation, which impairs the covalent binding between the cysteine residue at position 797 of EGFR and osimertinib, induces resistance to osimertinib. Currently, there are no effective therapeutic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acrylamides
Share to Aniline Compounds

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cetuximab

Share to Organophosphorus Compounds

Share to Panitumumab

Share to Piperazines

Share to Tumor Burden

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 28287083
DOI: 10.1038/ncomms14768
PMCID: PMC5355811

Genes

EGFR

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer.PMID 28287083Read ↗

Design, synthesis and evaluation of the Brigatinib analogues as potent inhibitors against tertiary EGFR mutants (EGFRdel19/T790M/C797S and EGFRL858R/T790M/C797S).Semantic proximity Read ↗

Effective Treatment of Lung Adenocarcinoma Harboring EGFR-Activating Mutation, T790M, and cis-C797S Triple Mutations by Brigatinib and Cetuximab Combination Therapy.Semantic proximity Read ↗

Fighting tertiary mutations in EGFR-driven lung-cancers: Current advances and future perspectives in medicinal chemistry.Semantic proximity Read ↗

Overcoming C797S mutation: The challenges and prospects of the fourth-generation EGFR-TKIs.Semantic proximity Read ↗

Brigatinib combined with cetuximab in the fifth-line treatment of non-small cell lung cancer with EGFR p.C797S mutation in critically ill patients: a report of two cases and literature review.Semantic proximity Read ↗

Recent Progress of Small-Molecule Epidermal Growth Factor Receptor (EGFR) Inhibitors against C797S Resistance in Non-Small-Cell Lung Cancer.Semantic proximity Read ↗

Cudratricusxanthone A Exhibits Antitumor Activities Against NSCLC Harboring EGFR L792H and G796R Triple Mutations via Regulating EGFR-ERK/AKT/STAT3 Signaling.Semantic proximity Read ↗

Characterization of the efficacies of osimertinib and nazartinib against cells expressing clinically relevant epidermal growth factor receptor mutationsSemantic proximity Read ↗

HJM-561, a Potent, Selective, and Orally Bioavailable EGFR PROTAC that Overcomes Osimertinib-Resistant EGFR Triple Mutations.Semantic proximity Read ↗

Repurposing CZC54252 to target EGFR C797S mutations and conquer Osimertinib resistanceSemantic proximity Read ↗

Design, synthesis and biological evaluation of 2-phenylaminopyrimidine derivatives as EGFR inhibitors.Semantic proximity Read ↗

Design, synthesis and biological evaluation of selective inhibitors against the L858R/T790 M/C797S mutant EGFR kinase based on the scaffold of brigatinib.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.